Immuno-oncology (I-O) is the treatment of cancer with immunotherapy by using therapies to stimulate or suppress the body’s immune system to fight cancer. Several distinct modalities of immunotherapy exist, including cytokines, vaccines, viruses, adoptive cell transfer, and checkpoint blockade using monoclonal antibodies.
Increasing research and development in cancer immunotherapy has resulted in the introduction of more effective and efficient treatment options. A paradigm shift from traditional chemotherapies to immunotherapies is driving market growth. According to GlobalData, the immuno-oncology market will be worth almost $125bn by 2024.
Stay on top of the competition by gaining a thorough understanding of the Immuno-Oncology market. GlobalData’s coverage of I-O includes in-depth market analyses and forecasts, as well as a deep dive into opportunities within the market. This series of reports provides expert-driven insight on the current and future I-O landscape, key unmet needs, and opportunities to compete that you won’t find anywhere else.
Download the guide to our Immuno-Oncology market report series here.
Click through our reports below to find out more, or contact us for more information on the latest reports available.